P
PBYI icon

Pitcairn’s Puma Biotechnology PBYI Stock Holding History

Pitcairn’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-27,558
Closed -$79K – 609
2022
Q1 		$79K Buy
+27,558
New +$71.3K 0.01% 602

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Pitcairn's PBYI Position: Q2 2022 in Review

Pitcairn sold out of Puma Biotechnology (PBYI) in Q2 2022, closing a stake of 27,558 shares — an estimated $79K sold.

Pitcairn first reported a position in PBYI in Q1 2022 and held it in 1 quarter. The position peaked at $79K in Q1 2022. 88 funds tracked by Wall St. Rank hold PBYI as of Q2 2022.

  • Pitcairn reported no remaining Puma Biotechnology position as of Q2 2022 after selling out during the quarter.
  • Pitcairn sold 27,558 Puma Biotechnology shares in Q2 2022, an estimated $79K.
  • Pitcairn first reported a position in Puma Biotechnology in Q1 2022 and held it in 1 quarter.
  • Pitcairn's Puma Biotechnology position peaked at $79K in Q1 2022.
  • 88 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2022.

Based on Pitcairn's 13F filing for Q2 2022, filed 12 Aug 2022.